{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:14:46Z","timestamp":1789348486989,"version":"build-2803163510"},"reference-count":197,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Zoonotic diseases are transmitted from animals to humans, and they impose a significant global burden by impacting both animal and human health. It can lead to substantial economic losses and cause millions of human deaths. The emergence and re-emergence of zoonotic diseases are heavily influenced by both anthropogenic and natural drivers such as climate change, rapid urbanization, and widespread travel. Over time, the unprecedented rise of new and re-emerging zoonotic diseases has prompted the need for rapid and effective vaccine development. Following the success of the COVID-19 mRNA vaccines, mRNA-based platforms hold great promise due to their rapid design, swift development and ability to elicit robust immune responses, thereby highlighting their potential in combating emerging and pre-pandemic zoonotic viruses. In recent years, several mRNA vaccines targeting emerging and re-emerging zoonotic viral diseases, such as rabies, Nipah, Zika, and influenza, have advanced to clinical trials, demonstrating promising immunogenicity. This review explores recent advances, challenges, and future directions in developing mRNA vaccines against emerging and re-emerging zoonotic viral diseases.<\/jats:p>","DOI":"10.3390\/v17070960","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T11:58:07Z","timestamp":1751975887000},"page":"960","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["mRNA Vaccine Development in the Fight Against Zoonotic Viral Diseases"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4586-6081","authenticated-orcid":false,"given":"Brandon E. K.","family":"Tan","sequence":"first","affiliation":[{"name":"ALPS Global Holding Berhad, The Icon, East Wing Tower Level 18-01 & Level 18-02, No.1 Jalan 1\/68F, Off Jalan Tun Razak, Kuala Lumpur 50400, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng Kong","family":"Tham","sequence":"additional","affiliation":[{"name":"ALPS Global Holding Berhad, The Icon, East Wing Tower Level 18-01 & Level 18-02, No.1 Jalan 1\/68F, Off Jalan Tun Razak, Kuala Lumpur 50400, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chit Laa","family":"Poh","sequence":"additional","affiliation":[{"name":"ALPS Global Holding Berhad, The Icon, East Wing Tower Level 18-01 & Level 18-02, No.1 Jalan 1\/68F, Off Jalan Tun Razak, Kuala Lumpur 50400, Malaysia"},{"name":"Nilai University, No.1, Persiaran Universiti, Putra Nilai, Bandar Baru Nilai, Nilai 71800, Negeri Sembilan, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"ref_1","first-page":"467","article-title":"Ecological sources of zoonotic diseases","volume":"23","author":"Slingenbergh","year":"2004","journal-title":"Rev. Sci. Tech.-Off. Int. Des \u00c9pizoot."},{"key":"ref_2","unstructured":"WHO (2025, May 13). Newsroom-Zoonoses. Fact Sheets, 29 July 2020. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/zoonoses."},{"key":"ref_3","unstructured":"WHO (2025). Zoonotic Diseases: Emerging Public Health Threats in the Region, WHO. Available online: https:\/\/www.emro.who.int\/about-who\/rc61\/zoonotic-diseases.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/nature06536","article-title":"Global trends in emerging infectious diseases","volume":"451","author":"Jones","year":"2008","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1098\/rstb.2001.0889","article-title":"Diseases of humans and their domestic mammals: Pathogen characteristics, host range and the risk of emergence","volume":"356","author":"Cleaveland","year":"2001","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1098\/rstb.2001.0888","article-title":"Risk factors for human disease emergence","volume":"356","author":"Taylor","year":"2001","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijregi.2022.12.001","article-title":"An epidemiological synthesis of emerging and re-emerging zoonotic disease threats in Cameroon, 2000\u20132022: A systematic review","volume":"7","author":"Tahmo","year":"2023","journal-title":"IJID Reg."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Saba Villarroel, P.M., Gumpangseth, N., Songhong, T., Yainoy, S., Monteil, A., Leaungwutiwong, P., Miss\u00e9, D., and Wichit, S. (2023). Emerging and re-emerging zoonotic viral diseases in Southeast Asia: One Health challenge. Front. Public Health, 11.","DOI":"10.3389\/fpubh.2023.1141483"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3201\/eid1112.040789","article-title":"Bushmeat hunting, deforestation, and prediction of zoonotic disease","volume":"11","author":"Wolfe","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/B978-0-444-52512-3.00216-3","article-title":"Emerging Zoonoses in Domesticated Livestock of Southeast Asia","volume":"68","author":"Hassan","year":"2014","journal-title":"Encycl. Agric. Food Syst."},{"key":"ref_11","unstructured":"Naicker, P.R. (2011). The impact of climate change and other factors on zoonotic diseases. Arch. Clin. Microbiol., 2."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Davidson, T. (2017). Vaccines: History, Science, and Issues, Bloomsbury Publishing. [1st ed.].","DOI":"10.5040\/9798216031635"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/emmm.201403876","article-title":"Vaccines for the 21st century","volume":"6","author":"Delany","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/08998280.2005.11928028","article-title":"Edward Jenner and the history of smallpox and vaccination","volume":"Volume 18","author":"Riedel","year":"2005","journal-title":"Baylor University Medical Center Proceedings"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0140-6736(68)91425-6","article-title":"Limitations of the germ theory","volume":"291","author":"Stewart","year":"1968","journal-title":"Lancet"},{"key":"ref_16","unstructured":"Calmette, A., Gu\u00e9rin, C., Boquet, A., and N\u00e8gre, L. (1927). La Vaccination Pr\u00e9ventive Contre La Tuberculose Par Le \u201cBCG\u201d, Masson et Cie."},{"key":"ref_17","first-page":"16635","article-title":"Vaccine development throughout history","volume":"13","author":"Saleh","year":"2021","journal-title":"Cureus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/infdis\/151.3.420","article-title":"Oral poliovirus vaccine: History of its development and use and current challenge to eliminate poliomyelitis from the world","volume":"151","author":"Sabin","year":"1985","journal-title":"J. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5501\/wjv.v1.i4.108","article-title":"History of polio vaccination","volume":"1","author":"Baicus","year":"2012","journal-title":"World J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ghattas, M., Dwivedi, G., Lavertu, M., and Alameh, M.-G. (2021). Vaccine technologies and platforms for infectious diseases: Current progress, challenges, and opportunities. Vaccines, 9.","DOI":"10.3390\/vaccines9121490"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kozak, M., and Hu, J. (2023). The integrated consideration of vaccine platforms, adjuvants, and delivery routes for successful vaccine development. Vaccines, 11.","DOI":"10.3390\/vaccines11030695"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bouazzaoui, A., Abdellatif, A.A., Al-Allaf, F.A., Bogari, N.M., Al-Dehlawi, S., and Qari, S.H. (2021). Strategies for vaccination: Conventional vaccine approaches versus new-generation strategies in combination with adjuvants. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13020140"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gote, V., Bolla, P.K., Kommineni, N., Butreddy, A., Nukala, P.K., Palakurthi, S.S., and Khan, W. (2023). A comprehensive review of mRNA vaccines. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032700"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0014-5793(94)00914-7","article-title":"Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA","volume":"352","author":"Megyeri","year":"1994","journal-title":"FEBS Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1546298","article-title":"Reversal of diabetes insipidus in Brattleboro rats: Intrahypothalamic injection of vasopressin mRNA","volume":"255","author":"Jirikowski","year":"1992","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: A biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100325","DOI":"10.1016\/j.jvacx.2023.100325","article-title":"Benefit-risk assessment of COVID-19 vaccine, MRNA (MRNA-1273) for males age 18\u201364 years","volume":"14","author":"Yogurtcu","year":"2023","journal-title":"Vaccine X"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-med-042420-112725","article-title":"mRNA vaccines in the COVID-19 pandemic and beyond","volume":"73","author":"Hogan","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101398","DOI":"10.1016\/j.omtm.2024.101398","article-title":"Research progress of mosquito-borne virus mRNA vaccines","volume":"12","author":"Sun","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Wang, Y.-S., Kumari, M., Chen, G.-H., Hong, M.-H., Yuan, J.P.-Y., Tsai, J.-L., and Wu, H.-C. (2023). mRNA-based vaccines and therapeutics: An in-depth survey of current and upcoming clinical applications. J. Biomed. Sci., 30.","DOI":"10.1186\/s12929-023-00977-5"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","article-title":"A trans-amplifying RNA vaccine strategy for induction of potent protective immunity","volume":"28","author":"Beissert","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Le, T., Sun, C., Chang, J., Zhang, G., and Yin, X. (2022). mRNA vaccine development for emerging animal and zoonotic diseases. Viruses, 14.","DOI":"10.3390\/v14020401"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","article-title":"The biogenesis, biology and characterization of circular RNAs","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12985-025-02645-6","article-title":"Revolutionizing immunization: A comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","article-title":"mRNA vaccines in disease prevention and treatment","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.gene.2012.07.034","article-title":"Characterization and evolution of 5\u2032 and 3\u2032 untranslated regions in eukaryotes","volume":"507","author":"Liu","year":"2012","journal-title":"Gene"},{"key":"ref_43","unstructured":"Centers for Disease Control and Prevention (CDC) (2025, May 13). 8 Zoonotic Diseases Shared Between Animals and People of Most Concern in the U.S., Available online: https:\/\/archive.cdc.gov\/www_cdc_gov\/media\/releases\/2019\/s0506-zoonotic-diseases-shared.html."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","article-title":"A novel coronavirus associated with severe acute respiratory syndrome","volume":"348","author":"Ksiazek","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/path.4454","article-title":"Molecular pathology of emerging coronavirus infections","volume":"235","author":"Gralinski","year":"2015","journal-title":"J. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/499388a","article-title":"Deadly pig virus slips through US borders","volume":"499","author":"Mole","year":"2013","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-015-0421-2","article-title":"Porcine epidemic diarrhea virus: An emerging and re-emerging epizootic swine virus","volume":"12","author":"Lee","year":"2015","journal-title":"Virol. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/jrms.JRMS_506_20","article-title":"Epidemiology of COVID-19: An updated review","volume":"26","author":"Halaji","year":"2021","journal-title":"J. Res. Med. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Maugeri, A., Barchitta, M., Battiato, S., and Agodi, A. (2020). Estimation of unreported novel coronavirus (SARS-CoV-2) infections from reported deaths: A susceptible\u2013exposed\u2013infectious\u2013recovered\u2013dead model. J. Clin. Med., 9.","DOI":"10.20944\/preprints202004.0052.v1"},{"key":"ref_51","unstructured":"WHO (2023). COVID-19 Epidemiological Update-22 December 2023, WHO. [162nd ed.]. Available online: https:\/\/www.who.int\/publications\/m\/item\/covid-19-epidemiological-update---22-december-2023."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jmv.25766","article-title":"Coronavirus disease 2019: What We Know?","volume":"92","author":"He","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, function, and evolution of coronavirus spike proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12098-020-03263-6","article-title":"A review of coronavirus disease-2019 (COVID-19)","volume":"87","author":"Singhal","year":"2020","journal-title":"Indian. J. Pediatr."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Alanagreh, L.a., Alzoughool, F., and Atoum, M. (2020). The human coronavirus disease COVID-19: Its origin, characteristics, and insights into potential drugs and its mechanisms. Pathogens, 9.","DOI":"10.3390\/pathogens9050331"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbrc.2004.09.106","article-title":"Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: Implication for developing subunit vaccine","volume":"324","author":"He","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Xia, X. (2021). Domains and functions of spike protein in SARS-CoV-2 in the context of vaccine design. Viruses, 13.","DOI":"10.3390\/v13010109"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Sharif-Yakan, A., Kanj, S.S., and Spindler, K.R. (2014). Emergence of MERS-CoV in the Middle East: Origins, transmission, treatment, and perspectives. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004457"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"9081","DOI":"10.1073\/pnas.1519235113","article-title":"Unraveling the drivers of MERS-CoV transmission","volume":"113","author":"Cauchemez","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1473-3099(19)30397-4","article-title":"First clinical trial of a MERS coronavirus DNA vaccine","volume":"19","author":"Yoon","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"115036","DOI":"10.1016\/j.celrep.2024.115036","article-title":"Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV","volume":"43","author":"Chao","year":"2024","journal-title":"Cell Rep."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Yong, C.Y., Ong, H.K., Yeap, S.K., Ho, K.L., and Tan, W.S. (2019). Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.01781"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"114347","DOI":"10.1016\/j.jviromet.2021.114347","article-title":"Development of a recombinant vaccine containing a spike S1-Fc fusion protein induced protection against MERS-CoV in human DPP4 knockin transgenic mice","volume":"299","author":"Jung","year":"2022","journal-title":"J. Virol. Methods"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trsl.2021.11.007","article-title":"Advances in mRNA and other vaccines against MERS-CoV","volume":"242","author":"Tai","year":"2022","journal-title":"Transl. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"199156","DOI":"10.1016\/j.virusres.2023.199156","article-title":"MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection","volume":"334","author":"Tai","year":"2023","journal-title":"Virus Res."},{"key":"ref_68","unstructured":"WHO (2020). Transmission of SARS-CoV-2: Implications for Infection Prevention Precautions, WHO. Available online: https:\/\/www.who.int\/news-room\/commentaries\/detail\/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.idc.2022.01.007","article-title":"SARS-CoV-2 transmission and prevention in the era of the Delta variant","volume":"36","author":"Meyerowitz","year":"2022","journal-title":"Infect. Dis. Clin. North Am."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"107839","DOI":"10.1016\/j.buildenv.2021.107839","article-title":"Lack of cross-transmission of SARS-CoV-2 between passenger\u2019s cabins on the Diamond Princess cruise ship","volume":"198","author":"Xu","year":"2021","journal-title":"Build. Environ."},{"key":"ref_71","first-page":"655","article-title":"Authorization of the first COVID-19 emergency vaccines: The matters arising","volume":"20","author":"Adedokun","year":"2021","journal-title":"EXCLI J."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Echaide, M., Chocarro de Erauso, L., Bocanegra, A., Blanco, E., Kochan, G., and Escors, D. (2023). mRNA vaccines against SARS-CoV-2: Advantages and caveats. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065944"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"Malvy","year":"2019","journal-title":"Lancet"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.coph.2021.08.002","article-title":"The 2013\u20132016 Ebola virus disease outbreak in West Africa","volume":"60","author":"Ohimain","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e1684","DOI":"10.1016\/S2214-109X(24)00260-2","article-title":"Ebola disease outbreak caused by the Sudan virus in Uganda, 2022: A descriptive epidemiological study","volume":"12","author":"Kabami","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","article-title":"The pathogenesis of Ebola virus disease","volume":"12","author":"Baseler","year":"2017","journal-title":"Annu. Rev. Pathol."},{"key":"ref_78","unstructured":"WHO (2025, May 13). Ebola virus disease. Fact Sheets, 24 April 2025. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ebola-disease."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Woolsey, C., Geisbert, T.W., and Dutch, R.E. (2021). Current state of Ebola virus vaccines: A snapshot. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1010078"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/infdis\/jix592","article-title":"Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease","volume":"217","author":"Meyer","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1017\/S0950268819000086","article-title":"Nipah virus infection: A review","volume":"147","author":"Shariff","year":"2019","journal-title":"Epidemiol. Infect."},{"key":"ref_82","first-page":"63","article-title":"Lessons from the Nipah virus outbreak in Malaysia","volume":"29","author":"Looi","year":"2007","journal-title":"Malaysian J. Pathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e01875-17","DOI":"10.1128\/JCM.01875-17","article-title":"Nipah virus infection","volume":"56","author":"Ang","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMoa1805376","article-title":"Transmission of Nipah virus\u201414 years of investigations in Bangladesh","volume":"380","author":"Nikolay","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"veae048","DOI":"10.1093\/ve\/veae048","article-title":"A systematic review on Nipah virus: Global molecular epidemiology and medical countermeasures development","volume":"10","author":"Tan","year":"2024","journal-title":"Virus Evol."},{"key":"ref_86","unstructured":"WHO (2025, May 13). Newsroom-Nipah virus. Fact Sheets, 30 May 2018. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/nipah-virus."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Liew, Y.J.M., Ibrahim, P.A.S., Ong, H.M., Chong, C.N., Tan, C.T., Schee, J.P., G\u00f3mez Rom\u00e1n, R., Cherian, N.G., Wong, W.F., and Chang, L.-Y. (2022). The immunobiology of Nipah virus. Microorganisms, 10.","DOI":"10.3390\/microorganisms10061162"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/viro.2000.0340","article-title":"Molecular characterization of Nipah virus, a newly emergent paramyxovirus","volume":"271","author":"Harcourt","year":"2000","journal-title":"Virology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"146ra107","DOI":"10.1126\/scitranslmed.3004241","article-title":"A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge","volume":"4","author":"Bossart","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"van Doremalen, N., Lambe, T., Sebastian, S., Bushmaker, T., Fischer, R., Feldmann, F., Haddock, E., Letko, M., Avanzato, V.A., and Rissanen, I. (2019). A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters. PLoS Neglected Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007462"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S493","DOI":"10.1093\/infdis\/jiz553","article-title":"Evaluation of a single-dose nucleoside-modified messenger RNA vaccine encoding Hendra virus-soluble glycoprotein against lethal Nipah virus challenge in Syrian hamsters","volume":"221","author":"Lo","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Loomis, R.J., DiPiazza, A.T., Falcone, S., Ruckwardt, T.J., Morabito, K.M., Abiona, O.M., Chang, L.A., Caringal, R.T., Presnyak, V., and Narayanan, E. (2021). Chimeric fusion (F) and attachment (G) glycoprotein antigen delivery by mRNA as a candidate Nipah vaccine. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.772864"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Pedrera, M., McLean, R.K., Medfai, L., Thakur, N., Todd, S., Marsh, G., Bailey, D., Donofrio, G., Muramatsu, H., and Pardi, N. (2024). Evaluation of the immunogenicity of an mRNA vectored Nipah virus vaccine candidate in pigs. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1384417"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Brandys, P., Albari\u00f1o, C.G., Jain, S., Merenkova, I., Shork, N.J., Deng, A., Vali\u00e8re, M., and Herold, J. (2024). A mRNA Vaccine Encoding for a 60-mer G Glycoprotein Nanoparticle Elicits a Robust Neutralizing Antibodies Response Against the Nipah Virus. bioRxiv.","DOI":"10.1101\/2024.08.05.606671"},{"key":"ref_95","unstructured":"Moderna (2022). Moderna Announces First Participant Dosed in a Phase 1 Trial of Its Nipah Virus mRNA Vaccine, mRNA-1215, Moderna. Available online: https:\/\/investors.modernatx.com\/news\/news-details\/2022\/Moderna-Announces-First-Participant-Dosed-in-a-Phase-1-Trial-of-its-Nipah-Virus-mRNA-Vaccine-mRNA-1215\/default.aspx."},{"key":"ref_96","unstructured":"WHO (2025, May 13). Newsroom-Influenza (seasonal). Fact Sheets, 28 February 2025. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal)."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Suarez, D.L. (2016). Influenza A virus. Animal Influenza, John Wiley & Sons, Inc.. [2nd ed.].","DOI":"10.1002\/9781118924341.ch1"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Abdelwhab, E.M., and Mettenleiter, T.C. (2023). Zoonotic animal influenza virus and potential mixing vessel hosts. Viruses, 15.","DOI":"10.3390\/v15040980"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/cid\/ciz803","article-title":"Lessons from influenza pandemics of the last 100 years","volume":"70","author":"Monto","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Yamamoto, S., Mizoue, T., Ujiie, M., Horii, K., Takeuchi, J.S., Konishi, M., Sugiura, W., and Ohmagari, N. (2025). Low Levels of Postvaccination Hemagglutination Inhibition Antibodies and Their Correlation With Influenza Protection Among Healthcare Workers During the 2024\u20132025 A\/H1N1 Outbreak in Japan. J. Infect. Dis., jiaf183.","DOI":"10.1093\/infdis\/jiaf183"},{"key":"ref_101","unstructured":"WHO (2025, May 13). Newsroom-Influenza (avian and other zoonotic). Fact Sheets, 3 October 2023. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(avian-and-other-zoonotic)."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"D49","DOI":"10.1016\/j.vaccine.2008.07.039","article-title":"The biology of influenza viruses","volume":"26","author":"Bouvier","year":"2008","journal-title":"Vaccine"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"397","DOI":"10.18388\/abp.2014_1857","article-title":"Introduction to molecular biology of influenza a viruses","volume":"61","author":"Szewczyk","year":"2014","journal-title":"Acta Biochim. Pol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/bmb\/ldz036","article-title":"Avian influenza viruses in humans: Lessons from past outbreaks","volume":"132","author":"Li","year":"2019","journal-title":"Br. Med. Bull."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1073\/pnas.0711815105","article-title":"Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus","volume":"105","author":"Pappas","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nbt.2436","article-title":"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: Principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Magini, D., Giovani, C., Mangiavacchi, S., Maccari, S., Cecchi, R., Ulmer, J.B., De Gregorio, E., Geall, A.J., Brazzoli, M., and Bertholet, S. (2016). Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161193"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41541-021-00420-6","article-title":"Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza","volume":"6","author":"Chivukula","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"eadc9937","DOI":"10.1126\/sciadv.adc9937","article-title":"A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets","volume":"8","author":"Lanfermeijer","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41541-023-00752-5","article-title":"Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection","volume":"8","author":"Kackos","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1038\/s41467-024-52940-z","article-title":"Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA","volume":"15","author":"Leonard","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_117","unstructured":"Sanofi (2021). Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine, Sanofi. Available online: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2021\/2021-06-22-05-00-00-2250633."},{"key":"ref_118","unstructured":"Moderna (2023). Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate, Moderna. Available online: https:\/\/investors.modernatx.com\/news\/news-details\/2023\/Moderna-Announces-Interim-Phase-3-Safety-and-Immunogenicity-Results-for-mRNA-1010-a-Seasonal-Influenza-Vaccine-Candidate\/default.aspx."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"126847","DOI":"10.1016\/j.vaccine.2025.126847","article-title":"A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults","volume":"50","author":"Soens","year":"2025","journal-title":"Vaccine"},{"key":"ref_120","unstructured":"Moderna (2022). Moderna Announces First Participants Dosed in Phase 1\/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates, Moderna. Available online: https:\/\/investors.modernatx.com\/news\/news-details\/2022\/Moderna-Announces-First-Participants-Dosed-in-Phase-12-Study-with-mRNA-1020-and-mRNA-1030-Seasonal-Influenza-Vaccine-Candidates\/default.aspx."},{"key":"ref_121","unstructured":"Pfizer (2024). Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18\u201364 Years of Age, Pfizer. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-provide-update-mrna-based-combination."},{"key":"ref_122","first-page":"31","article-title":"Update on rabies","volume":"2","author":"Jackson","year":"2011","journal-title":"Res. Rep. Trop. Med."},{"key":"ref_123","unstructured":"WHO (2025, May 13). Newsroom-Rabies. Fact Sheets, 5 June 2024. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/rabies."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-387040-7.00001-9","article-title":"Rabies virus transcription and replication","volume":"79","author":"Albertini","year":"2011","journal-title":"Adv. Virus Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1128\/JVI.76.7.3374-3381.2002","article-title":"Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response","volume":"76","author":"Faber","year":"2002","journal-title":"J. Virol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Armbruster, N., Jasny, E., and Petsch, B. (2019). Advances in RNA vaccines for preventive indications: A case study of a vaccine against rabies. Vaccines, 7.","DOI":"10.3390\/vaccines7040132"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2382499","DOI":"10.1080\/21645515.2024.2382499","article-title":"Development of mRNA rabies vaccines","volume":"20","author":"Fang","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Schnee, M., Vogel, A.B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., and Stitz, L. (2016). An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004746"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12985-022-01919-7","article-title":"An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs","volume":"19","author":"Li","year":"2022","journal-title":"Virol. J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41541-024-00925-w","article-title":"Safety and efficacy assessment of an mRNA rabies vaccine in dogs, rodents, and cynomolgus macaques","volume":"9","author":"Li","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1038\/s41467-023-39421-5","article-title":"Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses","volume":"14","author":"Hellgren","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Li, Q., Bai, H., Yu, X., Liu, Q., and Hu, R. (2025). Immunogenicity of Rabies Virus G-Protein mRNA Formulated with Muscle-Targeting Lipid Nanoparticles in Mice. Vaccines, 13.","DOI":"10.1101\/2025.01.06.631441"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomized, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Socha, W., Kwasnik, M., Larska, M., Rola, J., and Rozek, W. (2022). Vector-borne viral diseases as a current threat for human and animal health\u2014One Health perspective. J. Clin. Med., 11.","DOI":"10.3390\/jcm11113026"},{"key":"ref_136","unstructured":"WHO (2025, May 13). Vector-borne diseases. Fact Sheets, 26 September 2024. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/vector-borne-diseases."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: The results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41541-023-00656-4","article-title":"An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection","volume":"8","author":"Bollman","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_140","first-page":"001831","article-title":"Challenges on the development of a dengue vaccine: A comprehensive review of the state of the art","volume":"104","year":"2023","journal-title":"J. Gen. Virol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.4049\/jimmunol.147.9.3139","article-title":"Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc gamma receptors","volume":"147","author":"Mady","year":"1991","journal-title":"J. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified mRNA-LNP vaccines confer protection against experimental DENV-2 infection in mice","volume":"18","author":"Zhang","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.02482-20","article-title":"A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses","volume":"95","author":"Wollner","year":"2021","journal-title":"J. Virol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.virs.2022.07.003","article-title":"A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice","volume":"37","author":"He","year":"2022","journal-title":"Virol. Sin."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41541-023-00769-w","article-title":"Advancements in Rift Valley fever vaccines: A historical overview and prospects for next generation candidates","volume":"8","author":"Alkan","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/MS9.0000000000001680","article-title":"The pathogenicity and risk evaluation of Rift Valley virus to cause mysterious \u201cDisease X\u201d: An update on recent evidences","volume":"86","author":"Islam","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41541-023-00763-2","article-title":"A Rift Valley fever mRNA vaccine elicits strong immune responses in mice and rhesus macaques","volume":"8","author":"Bian","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Kitandwe, P.K., Rogers, P., Hu, K., Nayebare, O., Blakney, A.K., McKay, P.F., Kaleebu, P., and Shattock, R.J. (2024). A Lipid Nanoparticle-Formulated Self-Amplifying RNA Rift Valley Fever Vaccine Induces a Robust Humoral Immune Response in Mice. Vaccines, 12.","DOI":"10.3390\/vaccines12101088"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1089\/vbz.2017.2110","article-title":"Powassan virus: An emerging arbovirus of public health concern in North America","volume":"17","author":"Hermance","year":"2017","journal-title":"Vector-Borne Zoonotic Dis."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-ento-112408-085446","article-title":"Update on Powassan virus: Emergence of a North American tick-borne flavivirus","volume":"55","author":"Ebel","year":"2010","journal-title":"Annu. Rev. Entomol."},{"key":"ref_151","unstructured":"Centers for Disease Control and Prevention (CDC) (2024). Powassan Virus."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1016\/j.celrep.2018.11.082","article-title":"An mRNA vaccine protects mice against multiple tick-transmitted flavivirus infections","volume":"25","author":"VanBlargan","year":"2018","journal-title":"Cell Rep."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jmedent\/15.4.307","article-title":"Review Article: The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa","volume":"15","author":"Hoogstraal","year":"1979","journal-title":"J. Med. Entomol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/trstmh\/trv050","article-title":"The global distribution of Crimean-Congo hemorrhagic fever","volume":"109","author":"Messina","year":"2015","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_155","unstructured":"WHO (2025). Newsroom-Crimean-Congo Haemorrhagic Fever, WHO. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/crimean-congo-haemorrhagic-fever."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1309\/LMN1P2FRZ7BKZSCO","article-title":"Crimean-Congo hemorrhagic fever","volume":"46","author":"Shayan","year":"2015","journal-title":"Lab. Med."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Saunders, J.E., Gilbride, C., Dowall, S., Morris, S., Ulaszewska, M., Spencer, A.J., Rayner, E., Graham, V.A., Kennedy, E., and Thomas, K. (2023). Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model. eBioMedicine, 90.","DOI":"10.1016\/j.ebiom.2023.104523"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"e01568-21","DOI":"10.1128\/jvi.01568-21","article-title":"Nucleoside-modified mRNA vaccines protect IFNAR\u2013\/\u2013mice against Crimean-Congo hemorrhagic fever virus infection","volume":"96","author":"Appelberg","year":"2022","journal-title":"J. Virol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41541-024-01045-1","article-title":"Replicating RNA vaccine confers durable immunity against Crimean Congo hemorrhagic fever virus challenge in mice","volume":"9","author":"Leventhal","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41541-024-00887-z","article-title":"A replicating RNA vaccine confers protection in a rhesus macaque model of Crimean-Congo hemorrhagic fever","volume":"9","author":"Hawman","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Chen, T., Ding, Z., Li, X., Li, Y., Lan, J., and Wong, G. (2024). A mRNA Vaccine for Crimean\u2013Congo Hemorrhagic Fever Virus Expressing Non-Fusion GnGc Using NSm Linker Elicits Unexpected Immune Responses in Mice. Viruses, 16.","DOI":"10.3390\/v16030378"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Cueto, E., De La Fuente, J., and Lopez-Camacho, C. (2024). Potential of mRNA-based vaccines for the control of tick-borne pathogens in one health perspective. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1384442"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/1040841X.2020.1847037","article-title":"Severe fever with thrombocytopenia syndrome virus: A highly lethal bunyavirus","volume":"47","author":"Li","year":"2021","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1056\/NEJMoa1010095","article-title":"Fever with thrombocytopenia associated with a novel bunyavirus in China","volume":"364","author":"Yu","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3201\/eid2505.181463","article-title":"Endemic severe fever with thrombocytopenia syndrome, Vietnam","volume":"25","author":"Tran","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.3201\/eid2812.221183","article-title":"Severe fever with thrombocytopenia syndrome virus infection, Thailand, 2019\u20132020","volume":"28","author":"Rattanakomol","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"687","DOI":"10.46234\/ccdcw2023.132","article-title":"Advancements in the worldwide detection of severe fever with thrombocytopenia syndrome virus infection from 2009 to 2023","volume":"5","author":"Ai","year":"2023","journal-title":"China CDC Wkly."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cmi.2014.10.006","article-title":"A cluster of person-to-person transmission cases caused by SFTS virus in Penglai, China","volume":"21","author":"Jiang","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Kim, D., Lai, C.-J., Cha, I., and Jung, J.U. (2024). Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development. Viruses, 16.","DOI":"10.3390\/v16010128"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/cid\/ciz449","article-title":"First recognized human bite in the United States by the Asian longhorned tick, Haemaphysalis longicornis","volume":"70","author":"Wormser","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/cid\/ciz451","article-title":"Haemaphysalis longicornis is in the United States and biting humans: Where Do We Go From Here?","volume":"70","author":"Pritt","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e29203","DOI":"10.1002\/jmv.29203","article-title":"SFTSV Gn-Head mRNA vaccine confers efficient protection against lethal viral challenge","volume":"95","author":"Kim","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41541-023-00771-2","article-title":"mRNA vaccine encoding Gn provides protection against severe fever with thrombocytopenia syndrome virus in mice","volume":"8","author":"Kim","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e00769-24","DOI":"10.1128\/jvi.00769-24","article-title":"A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses","volume":"98","author":"Lu","year":"2024","journal-title":"J. Virol."},{"key":"ref_175","unstructured":"WHO (2025, May 13). Newsroom-Lassa fever. Fact Sheets, 5 December 2024. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lassa-fever."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14760584.2023.2290683","article-title":"Progress toward the development of Lassa vaccines","volume":"23","author":"Ly","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Aloke, C., Obasi, N.A., Aja, P.M., Emelike, C.U., Egwu, C.O., Jeje, O., Edeogu, C.O., Onisuru, O.O., Orji, O.U., and Achilonu, I. (2023). Combating Lassa fever in West African sub-region: Progress, challenges, and future perspectives. Viruses, 15.","DOI":"10.3390\/v15010146"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12985-024-02585-7","article-title":"Current perspectives on vaccines and therapeutics for Lassa Fever","volume":"21","author":"Warner","year":"2024","journal-title":"Virol. J."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Grant, D.S., Engel, E.J., Yerkes, N.R., Kanneh, L., Koninga, J., Gbakie, M.A., Alhasan, F., Kanneh, F.B., Kanneh, I.M., and Kamara, F.K. (2023). Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: A cross-sectional, population-based study. PLoS Neglected Trop. Dis., 17.","DOI":"10.1371\/journal.pntd.0010938"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1038\/s41467-023-41376-6","article-title":"A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection","volume":"14","author":"Ronk","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e00578-24","DOI":"10.1128\/jvi.00578-24","article-title":"An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice","volume":"98","author":"Hashizume","year":"2024","journal-title":"J. Virol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41591-022-01739-w","article-title":"Immune response to SARS-CoV-2 after a booster of mRNA-1273: An open-label phase 2 trial","volume":"28","author":"Chu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3201\/eid1409.086672","article-title":"Rudolf Virchow","volume":"14","author":"Schultz","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"ref_184","unstructured":"WHO (2017). Newsroom-One Health, WHO. Available online: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/one-health."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"963","DOI":"10.15212\/ZOONOSES-2022-0037","article-title":"One Health approach for the control of zoonotic diseases","volume":"2","author":"Erkyihun","year":"2022","journal-title":"Zoonoses"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Carpenter, A., Waltenburg, M.A., Hall, A., Kile, J., Killerby, M., Knust, B., Negron, M., Nichols, M., Wallace, R.M., and Behravesh, C.B. (2022). Vaccine preventable zoonotic diseases: Challenges and opportunities for public health progress. Vaccines, 10.","DOI":"10.3390\/vaccines10070993"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5491\/SHAW.2012.3.1.77","article-title":"Emerging zoonoses: The \u201cone health approach\u201d","volume":"3","author":"Rabozzi","year":"2012","journal-title":"Saf. Health Work"},{"key":"ref_188","unstructured":"WHO (2015, January 15). Blueprint for R&D preparedness and response to public health emergencies due to highly infectious pathogens. Proceedings of the Workshop on Prioritization of Pathogens, Geneva, Switzerland. Available online: https:\/\/www.who.int\/publications\/m\/item\/blueprint-for-r-d-preparedness-and-response-to-public-health-emergencies-due-to-highly-infectious-pathogens."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S1473-3099(22)00670-3","article-title":"WHO Pathogen X Conference","volume":"22","author":"Skyle","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Horefti, E. (2023). The importance of the One Health concept in combating zoonoses. Pathogens, 12.","DOI":"10.3390\/pathogens12080977"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"97","DOI":"10.53294\/ijfmsr.2024.6.2.0049","article-title":"mRNA-based vaccines for rapid response to emerging infectious disease outbreaks","volume":"6","author":"Banji","year":"2024","journal-title":"Int. J. Front. Med. Surg. Res."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Kowalzik, F., Schreiner, D., Jensen, C., Teschner, D., Gehring, S., and Zepp, F. (2021). mRNA-based vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9040390"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Uddin, M.N., and Roni, M.A. (2021). Challenges of storage and stability of mRNA-based COVID-19 vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9091033"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41541-023-00732-9","article-title":"Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine","volume":"8","author":"Li","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/mt.2014.133","article-title":"A cationic nanoemulsion for the delivery of next-generation RNA vaccines","volume":"22","author":"Brito","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Wang, H., Liu, X., Ai, X., Remant-Bahadur, K., Dick, T.A., Yan, B., Lu, T., Zhou, X., Luo, R., and Liu, M. (2023). Safe and effective delivery of mRNA using modified PEI-based lipopolymers. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020410"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/7\/960\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:06:42Z","timestamp":1760033202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/7\/960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":197,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["v17070960"],"URL":"https:\/\/doi.org\/10.3390\/v17070960","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}